Page 3 - Patrick Forde News Today

On Saturday night, the disabled community emphatically reinforced the message ‘Disability does not mean inability’ through the hosting of an exceptional Talent Show at the Prince Cave Hall. The entertaining production was staged by the National United Society of Blind Barbados (NUSB). The wealth of talent that exists was evident as participants exhibited their artistry in multiple artforms. The funds generated

Victoria Smurfit, the Irish actress once said, “If you’re Irish, it doesn’t matter where you go, you’ll find family!” That sentiment not only rings true for the Irish, but for Rockaway, which is a great big family in its own right. That’s why we think of the Rockaway St. Patrick’s Day Parade as a big

Analysis of a Phase II trial for non-small cell lung cancer has suggested neoadjuvant nivolumab improved five-year recurrence-free survival.

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

3. Parade Committee President Michael Benn (center) is joined by deputy grand marshals Brendan Mullaney, Sean Neal, Marianne “Skippy” Doyle, Patrick Forde, Walter Sanchez, Sheila Connors and Paulette Casey. While the rest of the city was preparing to feast on turkey, revelers in Rockaway were decked in green and dining on corned beef at the

Constable Patrick Forde said he was on mobile patrol along the Adams section of the ABC Highway on March 21, 2019, when he received information about a suspect in a murder case being transported in a red Mazda bearing the licence plate MC 92. Forde was one of nine witnesses giving testimony yesterday in the No. 3 Supreme Court in the trial of Hakeem Stuart, who has pleaded not guilty …

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

Canva; Everyday Health The annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research meetings of its kind, bringing together a range of researchers, from those who spend their time in the lab to those who focus on patients in the clinic. The meeting atmosphere is electric — even when it’s virtual. Here are five key studies that stood out during the first week of the virtual AACR meeting, held April 10–15, 2021. Lymphoma Progression Cut in ...

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients Combination increases complete response rate to 24% compared to chemotherapy alone Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting. Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with...